Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Stable Vitiligo
A legfontosabb adatok
- Ki végzi
- Second Affiliated Hospital of Wannan Medical College
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- Korai 1. fázis
- Résztvevők
- 29 fő, tervezett
- Kezdés
- 2025. febr. 5.
- Tervezett befejezés
- 2026. nov. 17.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- human induced pluripotent stem cell derived exosomes (GD-iExo-003)
- a placebo of exosomes derived from human induced pluripotent stem cell for injection
- A regiszteradat frissítve
- 2025. február 6.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with stable, localized vitiligo, a condition that causes white patches on the skin. It tests exosomes made from stem cells, given by microneedle injection, against a placebo.
- Életkor
- 18 to 60 years
- Nem
- All sexes
- A betegség stádiuma
- Stable localized vitiligo with a VIDA score of 0. No Koebner phenomenon (new patches after skin injury) for at least 1 year. Lesion area under 1% of body surface. Lesions stable for more than 6 months, at least 3 patches, with at least 2 larger than 2cm².
- Korábbi kezelés
- No other vitiligo treatment in the past 3 months, such as corticosteroids, JAK inhibitors, topical herbal medicines, depigmentation therapy, cell transplant surgery or phototherapy. Other vitiligo treatments must be stopped during the trial, except cosmetic cover-ups.
A részvétel fő kizáró okai
- Progressive vitiligo, moderate-to-severe vitiligo, or white area of 1% of body surface or more
- Other active pigment or inflammatory skin diseases
- Pregnant or breastfeeding women, or plans to conceive during the study and for 3 months after
- Other autoimmune diseases or major illnesses such as tuberculosis, AIDS, cancer, heart, brain blood vessel, liver or kidney disease
- Serious drug allergies, substance or alcohol abuse, or mental health conditions
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Agree to follow the trial treatment protocol and visit schedule, voluntarily enroll in the study, and provide written informed consent
- Aged 18-60 years old (inclusive of 18 and 60 years)
- Clinically diagnosed with stable localized vitiligo (in accordance with the 2021 Consensus on the Diagnosis and Treatment of Vitiligo); Stability criteria: ① A score of 0 on the Vitiligo Disease Activity (VIDA) scale; ② Clinical characteristics: white patches appear porcelain white, with clear or pigmented edges; ③ No Koebner phenomenon (for ≥1 year); ④ Wood's lamp examination: lesions appear white with clear boundaries, and the area under Wood's light is ≤ visual estimation area, indicating stability. Skin CT and dermatoscopy images may also be referenced for diagnostic assistance. Localization criteria: Refers to single lesions, with an area classified as grade 1 (lesion area <1% of total body surface area), where it is not yet possible to determine whether the presentation is segmental or non-segmental at the time of consultation
- Lesions have been stable for more than 6 months, with a number of foci ≥3, ensuring that at least 2 lesions have an area >2cm²
- Have no plans for conception during the study period and for 3 months after the last administration, and can adopt effective contraceptive measures
- Agree to suspend any other anti-vitiligo treatments outside of the study protocol during participation in this clinical research (excluding cosmetic cover-ups)
Ki nem vehet részt
- Those who have received other treatments for vitiligo within the recent past (within 3 months), such as corticosteroids, JAK inhibitors, topical herbal medicines, depigmentation therapy, melanocyte-keratinocyte transplant surgery, phototherapy, etc
- Individuals with clinically significant multiple or severe drug allergies, or those who have had serious allergic reactions to treatments, or where the investigator anticipates that the participant may be allergic to the study medication or any of its components
- Participants with other active pigmented skin diseases during the screening period, such as pityriasis alba, senile leukoderma, chemical/drug-induced vitiligo, hyperpigmentation due to malignancy, post-inflammatory hyperpigmentation, ataxia telangiectasia, tuberous sclerosis, melasma, congenital hypopigmentation disorders, etc
- Evidence of active inflammatory skin disease or skin condition during the screening period, such as atopic dermatitis, psoriasis, discoid lupus, leprosy, syphilis, seborrheic dermatitis, etc., which the investigator assesses might interfere with the evaluation of response and safety regarding vitiligo treatment
- Participants with a history or current diagnosis of other autoimmune diseases and major illnesses: tuberculosis, AIDS, malignancies, cardiovascular and cerebrovascular diseases, liver and kidney diseases, etc
- Individuals with a history of substance or alcohol abuse or those suffering from mental health conditions
- Participants diagnosed with progressive vitiligo or moderate-to-severe stable vitiligo
- Total depigmented area ≥1% of body surface area (BSA)
- Pregnant or breastfeeding women
- Abnormal blood test results that the investigator judges could affect the assessment of efficacy and safety of the participant or the trial outcomes
- Any other circumstances where the investigator believes that the participant's compliance may be affected or they are unsuitable to participate in this study
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 60 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Evaluate the efficacy of induced pluripotent stem cell-derived exosomes (iPSC-Exos) for the treatment of stable vitiligo
A vizsgálat 2 csoportja
- Exosomes groupA vizsgált kezelés
group1-low-dose group, 3 patients will receive doses of GD-iExo-003 at 1×10\^8 particles per 4 square centimeters of lesion area in 100 μL. group2-mid-dose group, 3 patients will receive doses of GD-iExo-003 at 3×10\^8 particles per 4 square centimeters of lesion area in 100 μL. group3-high-dose group, 3 patients will receive doses of GD-iExo-003 at 9×10\^8 particles per 4 square centimeters of lesion area in 100 μL. The administration method is microneedle injection, with each injection being 100 ul. Once every 2 weeks, for a total treatment duration of 3 months, with an additional follow-up period of 6 months
Kezelés: human induced pluripotent stem cell derived exosomes (GD-iExo-003)
- placebo groupPlacebo, összehasonlításként
Patients in this arm will be given a placebo. The administration method is microneedle injection, with each injection being 100 ul. Once every 2 weeks, for a total treatment duration of 3 months, with an additional follow-up period of 6 months.
Kezelés: a placebo of exosomes derived from human induced pluripotent stem cell for injection
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Exploratory Clinical Study on Induced Pluripotent Stem Cell Derived Exosomes (iPSC-Exos) for the Treatment of Stable Vitiligo
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT06810869: ki vehet részt
- A regiszteradat frissítve
- 2025. február 6.